Skip to main content

Improving treatment of drug-resistant epilepsy

Improving treatment of drug-resistant epilepsy

Epilepsy is the most common neurological disease after migraine but drug treatments fail in around 30% of cases. Our research into ketogenic diets has led to a new dietary treatment to improve patient quality of life.

Improving the health and quality of life in patients with drug-resistant epilepsy

Epilepsy is the most common neurological disease after migraine, affecting around 1 in 100 people in the UK, and 50 million people worldwide. Although a large array of drug treatments are available, these fail in around 30% of cases. Treatment of patients with devastating drug-resistant epilepsy often employs a low-carbohydrate (high-fat) diet, called the ketogenic diet, which although effective, is very difficult to maintain, and entails significant investment in NHS resources. Our research has identified and developed a new diet that is considerably easier for patients to use, and less reliant on NHS resources.  It may help in improving the health and quality of life in patients by significantly reducing seizure occurrence and intensity and enable many patients to reduce or even stop anti-epileptic medications.

Saving the NHS costs in patient treatment

Typically, the ketogenic diet is administered in an outpatient setting, although young children have a 5-10 day hospital admission. However, all patients are currently supported by specialist paediatric dietitian, clinical nurses, consultant biochemist, consultant neurologist, pharmacist, and diagnostic and monitoring services prior to treatment, with at least six monthly repeats. The new diet is likely to significantly reduce hospital staff time during treatment due to reducing dietary restrictions and subsequent need for support services. A recent US study suggests that the annual cost of drug-resistant epilepsy is $US4 billion, with individual health care costs at $US33613.

New approaches and applications

We are continuing our research into the development of new pharmacological approaches to reduce the restrictive nature of ketogenic diets whilst also looking at how the MCT ketogenic diet can potentially be used for improved patient treatment in other diseases including cancer, bipolar disorder and Alzheimer’s disease.

 “Through our innovative approach to understanding the treatment of drug-resistant epilepsy, we hope to have provided a new dietary treatment that will help patients with epilepsy lead a happier, healthier and safer life.” 

Further articles and videos on epilepsy research:

All you need is fats – for seizure control: Using amoeba to advance epilepsy research

Medium Chain Fatty Acids; In Progress report on new antiepileptic drugs

Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders

Social amoebae for epilepsy research

 

 

 

Explore Royal Holloway

Get help paying for your studies at Royal Holloway through a range of scholarships and bursaries.

There are lots of exciting ways to get involved at Royal Holloway. Discover new interests and enjoy existing ones

Heading to university is exciting. Finding the right place to live will get you off to a good start

Whether you need support with your health or practical advice on budgeting or finding part-time work, we can help

Discover more about our 21 departments and schools

Find out why Royal Holloway is in the top 25% of UK universities for research rated ‘world-leading’ or ‘internationally excellent’

They say the two most important days of your life are the day you were born, and the day you find out why

Discover world-class research at Royal Holloway

Discover more about who we are today, and our vision for the future

Royal Holloway began as two pioneering colleges for the education of women in the 19th century, and their spirit lives on today

We’ve played a role in thousands of careers, some of them particularly remarkable

Find about our decision-making processes and the people who lead and manage Royal Holloway today